$0.00
0.00%
Nasdaq, Fri, Sep 06 2024
ISIN
US00547W2089
Symbol
ADMP
Sector
Industry

Adamis Pharmaceuticals Corporation Stock price

$0.00
+0.00 100.00% 1M
-0.07 99.73% 6M
-0.70 99.97% YTD
-0.77 99.97% 1Y
-77.70 100.00% 3Y
-53.20 100.00% 5Y
-347.90 100.00% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
+0.00 0.00%
ISIN
US00547W2089
Symbol
ADMP
Sector
Industry

Key metrics

Market capitalization $350.00k
Enterprise Value $-5.92m
P/E (TTM) P/E ratio 0.00
EV/FCF (TTM) EV/FCF 0.63
EV/Sales (TTM) EV/Sales -1.64
P/S ratio (TTM) P/S ratio 0.10
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $3.62m
EBIT (operating result TTM) EBIT $-18.80m
Free Cash Flow (TTM) Free Cash Flow $-9.47m
Cash position $6.66m
EPS (TTM) EPS $-9.18
Short interest 1.30%
Show more

Is Adamis Pharmaceuticals Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Adamis Pharmaceuticals Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Adamis Pharmaceuticals Corporation:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Adamis Pharmaceuticals Corporation:

Buy
100%

Financial data from Adamis Pharmaceuticals Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '23
+/-
%
3.62 3.62
71% 71%
100%
- Direct Costs 5.52 5.52
53% 53%
152%
-1.90 -1.90
313% 313%
-52%
- Selling and Administrative Expenses 13 13
102% 102%
370%
- Research and Development Expense 2.97 2.97
70% 70%
82%
-18 -18
39% 39%
-504%
- Depreciation and Amortization 0.55 0.55
79% 79%
15%
EBIT (Operating Income) EBIT -19 -19
42% 42%
-519%
Net Profit -22 -22
61% 61%
-614%

In millions USD.

Don't miss a Thing! We will send you all news about Adamis Pharmaceuticals Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adamis Pharmaceuticals Corporation Stock News

Neutral
GlobeNewsWire
about one year ago
Company to begin trading under new ticker symbol “DMK” on September 8, 2023 Company to begin trading under new ticker symbol “DMK” on September 8, 2023
Neutral
GlobeNewsWire
about one year ago
SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) --  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.
Neutral
GlobeNewsWire
about one year ago
SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the closing of its public offering of 5,930,000 units, with each unit consisting of one share of common stock (or pre-funded warrant in lieu thereof) and one warrant to purchase one share of common stock. Each unit was sold at a public off...
More Adamis Pharmaceuticals Corporation News

Company Profile

Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development and sales of pharmaceutical, specialty biopharmaceutical and other drug products. It offers Symjepi product for allergy, respiratory, opioid overdose, and erectile dysfunction (ED), markets. The company was founded in June 2006 and is headquartered in San Diego, CA.

Head office United States
CEO Ebrahim Versi
Employees 11
Founded 2006
Website www.adamispharmaceuticals.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today